問卷

TPIDB > Search Result

Search Result

篩選

List

6Cases

2025-04-01 - 2029-09-30

Active
A phase 3, randomized, double-blind, placebo-controlled trial (PREVAIL) of Felzartamab in adult patients with IgA nephropathy.
  • Condition/Disease

    The percentage change in proteinuria from baseline to week 36 was assessed based on the urine protein/creatinine ratio (UPCR) measurement of 24-hour urine samples.

  • Test Drug

    Felzartamab

Participate Sites
8Sites

Recruiting8Sites

2024-10-03 - 2029-10-04

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2025-07-01 - 2030-10-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-06-13 - 2030-06-30

Active
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2021-12-31 - 2030-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2024-03-15 - 2031-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Not yet recruiting1Sites

Recruiting9Sites